An Open-label, Single Dose, Parallel Group Study to Assess the Effects of Smoking Status, Age and Body Size on the Pharmacokinetics, Safety, and Tolerability of Tasimelteon in Healthy Volunteers.

Trial Profile

An Open-label, Single Dose, Parallel Group Study to Assess the Effects of Smoking Status, Age and Body Size on the Pharmacokinetics, Safety, and Tolerability of Tasimelteon in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2012

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders; Insomnia; Major depressive disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 19 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
    • 19 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Nov 2011 Actual initiation date (Nov 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top